Evidence map›Paper›PMID 37870270›Full record

ArticleHepatology (Baltimore, Md.)2024

Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.

Claudia Campani, Ariane Vallot, Haroun Ghannouchi, Manon Allaire, Manon Evain, Philippe Sultanik, Sabrina Sidali, Lorraine Blaise, Dominique Thabut, Pierre Nahon and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Interpretive consistency of a qualitativeEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Article
  6. Lessons Learned from Liver-on-Chip Platform.Annals of biomedical engineering · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Claudia CampaniCordeliers Research Center, Sorbonne University, Inserm, Paris Cité University, "Functional Genomics of Solid Tumors" team, Ligue Nationale Contre le Cancer accredited team, Labex OncoImmunology, Paris, France.ORCID 0000-0003-3842-782
Ariane VallotRadiology Department, AP-HP, Sorbonne University, Universitary Hospital Pitié Salpêtriére, Paris, France.
Haroun GhannouchiInterventional Radiology Department, Avicenne Hospital, Paris-Seine-Saint-Denis Universitary Hospitals, AP-HP, Bobigny, France.
Manon AllaireHepato-gastroenterology Department, AP-HP, Sorbonne University, Pitié Salpêtriére Universitary Hospital, Paris, France.
Manon EvainHepato-gastroenterology Department, AP-HP, Sorbonne University, Pitié Salpêtriére Universitary Hospital, Paris, France.
Philippe SultanikHepato-gastroenterology Department, AP-HP, Sorbonne University, Pitié Salpêtriére Universitary Hospital, Paris, France.
Sabrina SidaliCordeliers Research Center, Sorbonne University, Inserm, Paris Cité University, "Functional Genomics of Solid Tumors" team, Ligue Nationale Contre le Cancer accredited team, Labex OncoImmunology, Paris, France.
Lorraine BlaiseLiver Unit, Avicenne Hospital, Paris-Seine-Saint-Denis Universitary Hospitals, AP-HP, Bobigny, France.
Dominique ThabutHepato-gastroenterology Department, AP-HP, Sorbonne University, Pitié Salpêtriére Universitary Hospital, Paris, France.
Pierre NahonCordeliers Research Center, Sorbonne University, Inserm, Paris Cité University, "Functional Genomics of Solid Tumors" team, Ligue Nationale Contre le Cancer accredited team, Labex OncoImmunology, Paris, France.
Olivier SerorCordeliers Research Center, Sorbonne University, Inserm, Paris Cité University, "Functional Genomics of Solid Tumors" team, Ligue Nationale Contre le Cancer accredited team, Labex OncoImmunology, Paris, France.
Nathalie Ganne-CarriéCordeliers Research Center, Sorbonne University, Inserm, Paris Cité University, "Functional Genomics of Solid Tumors" team, Ligue Nationale Contre le Cancer accredited team, Labex OncoImmunology, Paris, France.
Jean-Charles NaultCordeliers Research Center, Sorbonne University, Inserm, Paris Cité University, "Functional Genomics of Solid Tumors" team, Ligue Nationale Contre le Cancer accredited team, Labex OncoImmunology, Paris, France.ORCID 0000-0002-4875-9353
Mathilde WagnerRadiology Department, AP-HP, Sorbonne University, Universitary Hospital Pitié Salpêtriére, Paris, France.
Olivier SutterInterventional Radiology Department, Avicenne Hospital, Paris-Seine-Saint-Denis Universitary Hospitals, AP-HP, Bobigny, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsWe aim to assess the role of radiological response to atezolizumab-bevacizumab in patients with HCC to predict overall survival. APPROACH AND

resultsWe retrospectively included patients with HCC treated by atezolizumab-bevacizumab in 2 tertiary centers. A retrospective blinded analysis was performed by 2 radiologists to assess Response Evaluation Criteria in Solid Tumor (RECIST 1.1) and modified RECIST (mRECIST) criteria at 12 weeks. Imaging response and treatment decisions in the multidisciplinary tumor board at 12 weeks were registered. Among 125 patients, 9.6% and 20.8% had a response, 39.2% and 35.2% had stable disease, and 51.2% and 44% had progression, according to RECIST 1.1 and mRECIST, respectively, with a substantial interobserver agreement (k coefficient=0.79). Metastasis was independently associated with a higher risk of progression. Patients classified as responders did not reach median survival, which was 16.2 and 15.9 months for patients classified as stable and 9.1 and 9.0 months for patients classified as progressors, in RECIST 1.1 and mRECIST criteria, respectively. We observed a wide variability in the identification of progression in the multidisciplinary tumor board in clinical practice compared with the blind evaluation by radiologists mainly due to discrepancy in the evaluation of the increase in size of intrahepatic lesions. The appearance of new extrahepatic lesions or vascular invasion lesions was associated with a worse overall survival ( p =0.032).

conclusionsRECIST 1.1 and mRECIST criteria predict overall survival with more responders identified by mRECIST and the appearance of new extrahepatic lesion or vascular invasion was associated with a poor prognosis. A noticeable discrepancy was observed between patients classified as progressors at reviewing and the decision reached during the multidisciplinary tumor board.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAntibodies, Monoclonal, HumanizedBevacizumabHumansRetrospective StudiesTomography, X-Ray ComputedAntibodies, Monoclonal, HumanizedatezolizumabBevacizumab

Identifiers

PMID37870270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.